Selecta Biosciences, Inc.: Immune tolerance platform (ImmTOR) developed in combo with rare disease therapies. SEL-212 (chronic refractory gout) in COMPARE Ph 2 trial vs KRYSTEXXA®; topline data mid-2020. Gene tx pipeline in preclinical development with ImmTOR where re-dosing require. AskBio collab.
Based in...
US - New England
Clinical Stage
Phase l or ll
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Gene Therapy
480 Arsenal Way
Watertown, MA 02472
United States

Top 10 Holders of Selecta Biosciences, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
BVF, Inc. 17.21 8,294,547 21.57 13F 6/30/20
Mangrove Partners 13.58 6,546,780 17.02 13F 6/30/20
Vanguard Group, Inc. (Subfiler) 7.47 3,600,316 9.36 13F 6/30/20
Boxer Capital LLC 6.81 3,284,072 8.54 13F 6/30/20
The Vanguard Group, Inc. 6.65 3,209,337 8.34 Funds 8/31/20
Artal Group SA 6.02 2,900,000 7.54 13F 6/30/20
Marshall Wace North America LP 5.92 2,852,704 7.42 13F 6/30/20
Polaris Venture Management Co. V LLC 5.75 2,773,479 7.21 13F 6/30/20
Fidelity Management & Research Co. LLC 5.22 2,515,686 6.54 13F 6/30/20
Wasatch Advisors, Inc. 5.06 2,440,057 6.34 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.